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Background: Surgical site infections (SSIs) are common, occurring in up to 25% of > 4 million operations performed in
England each year. Previous trials of the effect of wound dressings on the risk of developing a SSI are of poor quality
and underpowered.
Methods/Design: This study is a feasibility and pilot trial to examine the feasibility of a full trial that will compare
simple dressings, no dressing and tissue-glue as a dressing. It is examining the overall acceptability of trial participation,
identifying opportunities for refinement, testing the feasibility of and validating new outcome tools to assess SSI, wound
management issues and patients’ wound symptom experiences. It is also exploring methods for avoiding performance
bias and blinding outcome assessors by testing the feasibility of collecting wound photographs taken in theatre
immediately after wound closure and, at 4–8 weeks after surgery, taken by participants themselves or their carers.
Finally, it is identifying the main cost drivers for an economic evaluation of dressing types. Integrated qualitative
research is exploring acceptability and reasons for non-adherence to allocation. Adults undergoing primary elective or
unplanned abdominal general surgery or Caesarean section are eligible. The main exclusion criteria are abdominal or
other major surgery less than three months before the index operation or contraindication to dressing allocation. The
trial is scheduled to recruit for nine months. The findings will be used to inform the design of a main trial.
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Discussion: This pilot trial is the first pragmatic study to randomise participants to no dressing or tissue-glue as a
dressing versus a simple dressing. Early evidence from the ongoing pilot shows that recruitment is proceeding well
and that the interventions are acceptable to participants. Combined with the qualitative findings, the findings will
inform whether a main, large trial is feasible and, if so, how it should be designed.
Trial registration: ISRCTN49328913. Registered on 20 October 2015.
Keywords: Pilot study, Feasibility study, Randomised controlled trial, Wound dressing, Abdominal surgery, Caesarean
section, Wound dressing, Surgical site infectionBackground
It has been estimated that over 200 million operations
are performed worldwide each year and about 4.5 million
in England [1]. At the end of each procedure the skin
edges of the wound are approximated using sutures or
clips. Closing a surgical incision in this way creates what is
called ‘a closed primary wound’. Following most surgery
in adults, it is standard practice to cover closed primary
wounds with a dressing. However, it is rare to apply dress-
ings to closed primary wounds in children and in some
specialist areas of adult surgery [2]. There are many differ-
ent types of dressing available. They range from simple
(basic) to complex (advanced) dressings; the latter may
have absorbent or low adherence properties and some
may interact with the wound to improve healing. The
costs of different dressings vary too, from a few pence for
basic wound contact dressings to over £15 for advanced
antimicrobial dressings [3].
Evidence about the effects of wound dressings on surgical
wound healing in both adult and paediatric practice has
been systematically reviewed [4]. The review found no
evidence to suggest that covering surgical wounds with
dressings reduces the risk of a surgical site infection (SSI)
or that one wound dressing is more effective than another
in reducing scarring, controlling pain, promoting patient
acceptability or ease of dressing removal. However, the
review authors also found that the available evidence was of
poor quality; most studies were small and judged to be at
high risk of bias. They acknowledged the logistical challenge
of conducting a sufficiently large randomised controlled trial
(RCT) to detect a small target difference in the frequency of
SSIs with adequate power; a small target difference is likely
to be required because of the high cost of a SSI [5]. The
authors suggested that choices between wound dressing
strategies (between dressing versus no dressing as well as
between different dressings) could be based instead on their
effects on dressing costs and patient acceptability issues,
such as managing exudate and symptoms.
SSIs complicate up to 25% of surgical procedures [6–8].
Many SSIs resolve with simple antibiotic treatment but the
more serious SSIs cause morbidity and pain, discomfort
and inconvenience for patients. SSIs are costly for health
services; the average cost of a SSI has been estimated tobe at least £4600 (lower 95% confidence limit) [5]. After
some operations, a SSI can threaten the principal
outcome of the operation, the future health of the
patient and possibly even their life [9–13]. Therefore,
every effort is made before, during and after surgery
to minimise the risk of developing a SSI.
A key challenge in designing a RCT to evaluate the
effect of an intervention on SSI is choosing a method to
assess SSI that is feasible for a large RCT and satisfies a
wide range of stakeholders likely to have an interest in
the findings. Definitions of a SSI have been described in
another review [14], which concluded that SSI definitions
varied between surveillance programmes and hospitals
and lacked good agreement. The authors recommended
that future research should focus on developing a SSI
measure with satisfactory psychometric properties; the
measure should be formulated with the objective of
detecting SSIs that are important to patients and health
services, include post-discharge surveillance, and be suit-
able for application in everyday settings.
The Bluebelle study has been funded by the National
Institute for Health Research (NIHR) Health Technology
Assessment (HTA) programme with the aim of establishing
whether it is possible to carry out a large RCT to compare
the effectiveness and cost-effectiveness of wound dressing
types or no dressing on participant outcome [15]. It also
aims to develop new and better outcome measures for the
evaluation of wound dressings to use in a main trial. The
Bluebelle study has two parts, Phase A and Phase B. Phase
A comprised:
 case studies in general abdominal and obstetric
surgery to understand and explore the current use of
dressings and views about not using dressings [16];
 a survey of dressings currently used after primary
wound closure [17];
 a review of the effectiveness and costs of dressings
and contextual information (to update a Cochrane
review [4]);
 development and validation of questionnaire tools
to assess SSI after discharge [18] and practical
wound management and participant symptom
experience; [19]
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wound closure and, through literature review,
non-participant observations in theatres and interviews
with surgeons;
 several meetings with people who had had surgery
during Phase A to consider key aspects of the study
and participants’ involvement, including information
from participants’ interviews.
Phase B, a feasibility and external pilot trial [20] in-
formed by Phase A, is the subject of this protocol paper.
Aims and objectives
The overall aim of Phase B of the Bluebelle Study is to
carry out a feasibility and external pilot trial to establish
whether it is possible to carry out a large definitive RCT.
Based on findings from Phase A, the pilot trial is designed
to investigate the practicability of an RCT to compare the
effectiveness and cost-effectiveness of simple dressings,
tissue adhesive used as a dressing (glue-as-a-dressing) and
no dressing. The specific objectives are to:
1. Establish the numbers of potentially eligible
participants at different hospitals who can be
approached about the trial, and the proportions
confirmed as eligible, recruited and randomised
2. Pilot the randomisation process and attempt to
address any issues before progressing to a main trial,
including the risk of performance bias if allocation is
revealed before wound closure
3. Assess acceptability of the trial interventions and
processes to participants and clinical staff using
qualitative research methods, including methods to
promote adherence
4. Assess adherence to dressing type allocation and the
follow-up protocol and reasons for non-adherence
5. Assess the feasibility of collecting a range of
secondary outcomes and resource use
6. Establish the validity and reliability of
questionnaire tools for identifying SSI (wound
healing questionnaire [WHQ]) and describing
wound management (wound management
questionnaire [WMQ]) and a participant’s
experiences of wound care (wound experience
questionnaire [WEQ])
7. Explore the feasibility of obtaining digital
photographs of wounds taken by theatre personnel
in theatre after wound closure and, at 4–8 weeks
after surgery, taken by participants themselves or
their carers
8. Explore aspects of the trial design and conduct with
a patient and public involvement group to inform
the conduct of Phase B and the design of a future
main trial, following INVOLVE guidance [21]Methods/Design
Study design
Phase B of the Bluebelle study is a pragmatic feasibility
and pilot three-group parallel RCT (Fig. 1), using both
quantitative and qualitative research methods. A SPIRIT
Figure shows the different data colelction steps of the pilot
trial (Fig. 2); a completed SPIRIT checklist is available as
an additional file (Additional file 1: SPIRIT checklist).
Trial registration, research approvals and research
governance
The trial is registered with Current Controlled Trials;
ISRCTN49328913 was assigned on 20 October 2015.
The sponsor for the trial is University Hospitals Bristol
NHS Foundation Trust (research@uhbristol.nhs.uk) and
has responsibility for monitoring trial conduct.
The funder and sponsor have no role in: study design;
data collection, management or analysis; writing of
reports; or any future decisions to submit reports for
publication. The funder appointed an independent Study
Steering Committee, overseeing both Phase A and Phase B.
The funder and the Research Ethics Committee (REC)
agreed that a Data Monitoring and Safety Committee was
unnecessary. Phase B was coordinated by the Clinical Trials
and Evaluation Unit. A Study Executive Group monitors
progress approximately monthly.
Study population
The setting for the research is secondary care, i.e. acute
and maternity NHS hospitals. Patients aged 16 years or
older undergoing primary elective or unplanned open or
laparoscopic abdominal general surgery (including, but
not limited to, gastrectomy for benign or malignant disease,
cholecystectomy, anti-reflux procedures, hepatic resection,
small or large bowel resection for benign or malignant con-
ditions, abdominal wall hernia surgery [inguinal, femoral,
incisional, epigastric and para-umbilical]) or elective or un-
planned obstetric surgery (Caesarean section) are eligible.
Patients undergoing simultaneous abdominal and chest
surgery are eligible but only the abdominal wounds are allo-
cated to one of the study interventions. At the time of re-
cruitment, research nurses emphasise the need to attend a
follow-up clinic 4–8 weeks after surgery and do not recruit
patients who are unable to do so.
Patients meeting the above criteria but with any of the
following characteristics are ineligible:
 abdominal or other major surgery less than three
months before the index operation;
 the surgeon intends to ‘close’ the wound with tissue
adhesive (glue);
 any contraindication to one of the dressing
allocations including allergy to dressings;
 surgery where no skin incision occurs;
Fig. 1 Trial schema. Schema showing the pathway for patients recruited into the Bluebelle Phase B external pilot trial, including the double randomisation
Fig. 2 SPIRIT figure. The figure shows the phases of the trial and data collection time points
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 inability to complete patient-reported outcome
questionnaires;
 detained in the prison service.
All reasons for ineligibility are being recorded in the
trial screening log, allowing the trial results to be reported
in accordance with the CONSORT guidelines.
Eligible patients are provided with written information
(invitation letter and participant information leaflet [PIL]
(Additional file 2), reviewed by the REC) and given as long
as possible to consider the study before being approached
for participation (usually more than 4 h for elective surgery
and usually more than 1 h for unplanned surgery). Those
having elective surgery may also be given these documents
at a clinic visit before the operation or be sent them in
advance of admission. Research nurses or surgeons, who
are responsible for approaching potential participants, do
not request consent if a patient asks for longer thinking
time and do not approach any patient who appears visibly
distressed.
Participants are also asked to consent to four optional
aspects of the trial, designed to explore feasibility
(Additional file 3). The first relates to an interview
about the acceptability of, and adherence to, the allo-
cated dressing type (objectives 3 and 4). The second
allows a local member of the research team to take a
photograph of the wound(s) in the operating theatre,
immediately after wound closure (objective 2). The
third relates to the participant’s willingness to take a
photograph of their wound(s) themselves 4–8 weeks after
the operation and to send it to the research team
(described to participants as a ‘wound selfie’, a term which
was readily understood; objective 7). The fourth covers
consent for a skin transfer to be applied after the operation
to remind staff that the participant is in the study.
Surgery is carried out according to local protocols for
the operation. Apposition of wound edges and the method
of closure of the skin is at the discretion of the surgeon
and may include sutures, clips, wound closure strips or
combinations of these wound closure methods.
Randomisation
Participants are randomised to one of three dressing
groups. Participants are also randomised to disclosure of
the dressing group allocation to the surgeon before
wound closure or after wound closure. These two rando-
misations create six groups (Fig. 1). Both randomisations
are in blocks of varying size and stratified by hospital
Trust and specialty (abdominal surgery/obstetric surgery).
The sequences of random allocations were generated by
computer in advance of starting to recruit. Local research
team members access a participant’s allocation via the
Internet. The allocation is concealed until a participant’seligibility and consent have been documented and infor-
mation to identify the participant uniquely has been
entered.
At the beginning of the operation, a member of the local
research team (trainee or consultant surgeon/research
midwife or nurse) logs on to the randomisation website
(within the study database) using a secure password-
protected computer system and enters the information
needed to proceed to randomise the participant. Depend-
ing on the randomisation result, the dressing group alloca-
tion is disclosed immediately or the user is advised to log
back into the website after the wound has been closed and
enter the time of wound closure, after which the allocation
is disclosed.
The second randomisation, the disclosure of allocation
before or after wound closure, relates to objective 2.
During preliminary discussions about the trial, the trials
unit proposed that randomisation should occur after
wound closure, to prevent surgeons closing the wound
in different ways depending on the allocation, but surgeons
considered that this would be problematic. The second
randomisation allows the trial to test the feasibility of
randomising after wound closure to be tested. Moreover, if
photographs of the closed wound can be obtained in the
operating theatre and subsequently assessed for the quality
of wound closure, the effect of timing of randomisation on
wound closure can be investigated.
Blinding
It is not possible to blind surgeons, participants or staff
caring for participants to the dressing allocation. How-
ever, we plan to blind research staff assessing outcomes
4–8 weeks after randomisation and methods to achieve
blinding are being piloted to test their feasibility and
acceptability for the main trial. These include requiring
the reference SSI assessment and the WHQ to be com-
pleted by healthcare professionals who have not been in-
volved in a participant’s care during the index admission.
(The study also requires these assessments to be done
by different people, in order to validate the WHQ.) The
success of blinding among assessors of SSI 4–8 weeks
after randomisation (healthcare professionals completing
the reference SSI assessment or the WHQ) is being
assessed by asking them which study group they think
that the participant is allocated to.
If the occurrence of an SSI can be assessed from a
photograph after a dressing has been removed, the as-
sessment of the photograph could be blinded. For this
reason, the trial is testing the feasibility of participants
submitting wound selfies securely to the trial database.
Integrated qualitative research
A qualitative study is integrated into the pilot study, to
provide insights into the feasibility and potential design
Table 1 Examples of commonly used simple dressings
Bioclusive®
C-View®
Hydrofilm®
Opsite®
Mepore®
Tegaderm®
Table 2 Examples of commonly used types of tissue adhesive
Dermabond ProPen®
Epiglu®
Histoacryl®
LiquiBand®
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to explore participants’ experiences and the acceptability
of participating in the trial, staff experiences of delivering
trial processes/follow-up, and participant/staff perspec-
tives on reasons for protocol deviations. All patients who
agree to participate in the pilot RCT are also asked if they
are willing for their contact details to be shared with the
qualitative research team. Patients who provide written
consent to be contacted form the sampling frame for the
interviews. Potential interviewees are purposefully sam-
pled from this frame, with the intention of including a
range of individuals based on the following criteria:
 surgical specialty (upper GI, lower GI, or obstetric);
 surgical approach (laparoscopic or open procedures);
 nature of hospital admission (elective or unplanned);
 Bluebelle study allocation (simple dressing, ‘no
dressing’ or ‘glue-as-a-dressing’).
Healthcare professionals considered to be ‘key infor-
mants’ are purposefully selected for potential interview.
‘Key informants’ are defined as any individual with respon-
sibility for caring for Bluebelle participants or delivering as-
pects of the pilot RCT (e.g. recruitment, randomisation,
follow-up).
Topic guides have been developed in the light of earlier
findings (Phase A [16]) and are being iteratively developed
in light of emerging findings as data collection and ana-
lysis proceeds. Interviews will be conducted face-to-face
or via telephone by members of the qualitative research
team (LR and CM).
Interviews with participants explore the acceptability
of trial interventions and trial processes, reasons for
withdrawal (if appropriate) and sources of non-adherence
(i.e. instigated by staff or participants themselves). Partici-
pants may be interviewed at two time points: soon after
surgery (within a week); and around their 4–8 week follow-
up visit/assessment. A major finding from the qualitative
research during Phase A was that clinical staff anticipated
challenges in delivering the trial in practice. Therefore, in-
terviews with healthcare professionals are exploring their
experiences of implementing study protocols in practice
and perceived reasons for non-adherence.
Trial interventions
Participants are randomised to one of three standard
dressing groups: simple dressing (the comparator, be-
lieved to represent usual care [17]), no dressing or glue-
as-a-dressing.
A simple dressing is defined as a covering (opaque or
transparent) that is applied directly to an already closed
wound, over the entirety of the wound, adherent around
its entire perimeter or surface in contact with the skin.
It may or may not have absorbent properties. Table 1shows examples of commonly available simple dressings.
Hospital Trusts may have other types available and use
the dressing that represents usual care.
Tissue adhesives are topical skin adhesives. In this
trial, they are applied according to the manufacturers’
instructions and must be applied only to the surface of
an already closed primary wound, acting as a dressing
(not to close the wound, i.e. below skin level). A recent sur-
vey found that glue-as-a-dressing is a dressing strategy that
is often used by general surgeons [17] but it is considered
here as one of the two interventions, compared with a
simple dressing (the comparator). Table 2 shows examples
of commonly available tissue adhesives that can be used.
In the no dressing group, at the end of the operation
when the skin has been closed, no simple dressing or
tissue adhesive is applied to the wound. The wound is
therefore left exposed without a covering as is the stand-
ard approach for many types of surgery, particularly in
children [15].
The following aspects of wound care apply to all
interventions:
 a participant’s wounds should be dressed according
to the participant’s treatment allocation throughout
their hospital stay;
 when a participant has more than one wound
(e.g. multiple port sites for laparoscopic surgery),
all the eligible wounds are dressed according to
the treatment allocation;
 re-dressing of a wound in hospital may be needed if
there is slow discharge or ongoing seepage of fluid
(‘ooze’) from the wound in the first 24 h or if a SSI
occurs (i.e. after the outcome of interest has been
ascertained). For the former, a simple gauze swab
can be applied to the area that is oozing; this is
allowed in the no dressing group as well as the
other groups. The swab should be taped in place
temporarily and not around its entire perimeter.
Fig. 3 Skin transfers. Image shows a skin transfer applied near to the
wound(s) to promote adherence to the randomised dressing allocation
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Table 3. If oozing continues, the clinical team may
apply any dressing to the wound (or re-suture it if
necessary); where this represents deviation from
the allocated dressing, the action is documented in
the case report forms (CRFs);
 Co-interventions that may influence SSI rates (e.g.
the use of prophylactic antibiotics and other aspects
of pre-, peri- or postoperative care) will be allowed
at the discretion of the team and hospital looking
after the participants. Their distribution by allocated
group is being monitored, in view of the risk of bias
due to differential implementation of co-interventions
when the usual care team is not blinded to the
allocated dressing. This information will inform
decisions about the need to standardise care when
designing the main trial;
 To encourage adherence to treatment allocation,
colour-coded skin transfers showing the study logo
and the dressing allocation are provided. These are
applied on the participant’s skin, near to the surgical
wound(s), as a reminder to healthcare professionals
looking after the patient about the patient’s
participation in the trial and the allocated dressing
strategy (Fig. 3). The skin transfer disappears over
time and is not visible by the time of the 4–8-week
assessment.
Study centres and surgeons
Four NHS Hospital Trusts are taking part, one of which
is recruiting participants having either abdominal surgery
or Caesarean section. (Three Trusts had agreed to take part
at the outset and a fourth Trust, recruiting patients having
abdominal surgery, joined in month 6.) All general surgical
teams carry out a wide range of operations. The participat-
ing obstetric unit carries out about 1800 Caesarean sections
each year. Since the operations are all being carried out as
part of the usual care of participants, there are no restric-
tions on operating personnel or ward care.
Primary outcome
The primary outcome is successful screening of a par-
ticipant, determination of the participant’s eligibility and
consent to be randomised in the pilot trial, at the timeTable 3 Example of swabs that can be used to manage wound
exudate
Gauze swabs
Filmated gauze swabs
Non-woven fabric swabs
Filmated non-woven fabric swabs
Knitted viscose
Paraffin gauze dressingsof randomisation. This information, together with the
denominator describing the total number of participants
approached, will establish whether recruitment into the
main trial is possible.Secondary outcomes
These will include:
1. Adherence to disclosure of dressing category
allocation at the designated time
2. Adherence to the allocated dressing type by the
usual care team during the index hospital admission
and, if applicable, reason for non-adherence
3. Quality and completeness of the data for different
outcomes anticipated to be measured in the main
trial (see below; assessed at different times),
including component assessments contributing to an
overall judgement about the occurrence of a SSI
4. Adherence to the follow-up schedule
5. Documentation of co-interventions (e.g. details of
hair removal, use of skin cleansing agents, type of
wound closure methods, prescription of prophylactic
antibiotics) and classification of surgery as ‘clean’,
‘contaminated’ or ‘dirty’ at the time of the operation
6. Completion of the reference SSI assessment at 4–8
weeks by a blinded observer
7. Completion of a wound healing questionnaire (WHQ
[18] at 4–8 weeks by a blinded observer and by the
participant
8. Completion of a wound management questionnaire
(WMQ; developed during Phase A) up to 4 days after
randomisation by an observer or the participant (if
discharged early, e.g. day-case surgery)
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(WEQ; developed during Phase A) up to 4 days after
randomisation by the participant
10. Assessment of wounds from digital photographs at
4–8 weeks, if submitted
Bluebelle is a feasibility study and some of these sec-
ondary outcomes were developed in Phase A and are
being piloted in Phase B. Therefore, detailed scoring
methods are not currently available. We will report the
questionnaire response rates, the number of fully com-
pleted questionnaires and rates of missing items in this
pilot RCT as part of the evaluation of the acceptability
of the new questionnaires to patients. The data from
the pilot trial are also being used to validate some of
the questionnaires.Anticipated outcomes in a subsequent main trial
The following outcomes are expected to be assessed in a
main trial; the ability to collect these outcomes is, there-
fore, a key focus of the pilot trial:
1. Occurrence of a SSI up to 4–8 weeks after
randomisation (primary)
2. Wound management questionnaire
3. Patient reported outcomes: wound experience
questionnaire, documenting symptoms and
experiences of the wound and dressings, and generic
health status, assessed by the EQ-5D-5L [22]
4. Wound complications arising up to 4–8 weeks after
randomisation
5. Resource use up to 4–8 weeks, including length of
postoperative hospital stay, rates of re-admission and
durationTrial procedures and data collection up to four days after
randomisation
The schedule of data collection is described in the
SPIRIT Figure (Fig. 2).
Surgery and closure of wounds takes place as per usual
practice. A member of theatre personnel, or research team,
records: (1) the time taken to close the wound; (2) use of
laparoscopic or open surgical methods; and (3) the method
of wound closure. A member of theatre personnel or re-
search team may also take one or more digital photographs
of the wound(s). If randomised to disclosure of allocation
after wound closure, the time of completing wound closure
must be entered into the database to obtain the allocation.
A range of methods are being used to promote adherence
to the randomised dressing allocations in hospital, adapted
to the circumstances of participating hospitals. These in-
clude simple labels, to be attached to medical notes or
placed by the bedside, as well as skin transfers (Fig. 3).Up to four days after surgery, after any early wound
care that is required, a healthcare professional completes
the WMQ. This questionnaire captures information about
aspects of the participant’s wound management. If dis-
charged early, e.g. after day-case surgery or the day after
surgery, the research team gives the participant the WMQ
to complete by day 4 and send back to the trials unit in a
pre-paid envelope.
The local research team gives each participant the
WEQ to complete up to four days after surgery. For par-
ticipants who are in hospital at this time, the WEQ is
collected by the research team. If discharged early, e.g.
after day-case surgery or the day after surgery, the par-
ticipant completes the WEQ at home by day 4 and sends
it back to the trials unit in a pre-paid envelope.Data collection up to 4–8 weeks after randomisation
Local research teams give each participant a copy of
the EQ-5D-5L and a pre-paid reply envelope to take
home and instruct them to complete and return it if
a wound becomes infected or problematic. The reason
for asking for the EQ-5D-5L to be completed is to
try to document the peak impact of a wound problem
on health status to inform a future health economic
evaluation.
Several follow-up assessments are required 4–8 weeks
after randomisation. First, the participant needs to
complete a copy of the EQ-5D-5L and the WHQ; these
questionnaires can be given to participants at discharge
from hospital or posted shortly before they fall due.
Around this time, participants who have agreed to send
a photograph may also be sent an email or text message
including a web-link that allows them to upload a
photograph securely. Then, a blinded health professional
needs to complete the WHQ; this can be done face-to-
face, typically at the same clinic attendance but before
the reference SSI assessment, or administered by tele-
phone. Finally, the face-to-face reference SSI assessment
is completed by a blinded health professional, who must
be different to the one completing the WHQ; this as-
sessment includes eliciting information about potential
wound-related complications. Whenever possible, the
face-to-face clinic visit is arranged to coincide with a
usual care clinic appointment. When this is not possible,
travel expenses are offered to the participant. For
women who have had a Caesarean section, the WHQ
questionnaire is administered by telephone and re-
search midwives then carry out the reference SSI as-
sessment at a home visit.
To promote retention, reminders are sent out to par-
ticipants who fail to return postal questionnaires promptly.
Participants who fail to attend for the face-to-face SSI
assessment are offered further appointments.
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The operation and medical notes, and other information
held electronically on hospital information systems, provide
source data for participant demographic and baseline
information, operation details and postoperative morbidity.
The completed participant questionnaires and observer-
reported assessments of SSI and wound management are
the primary data source for these measures. The data
source for secondary adverse outcomes will be the partici-
pant’s medical notes. Wound photographs are the primary
data source for this outcome.
Staff at participating centres record data on paper CRFs,
then use a password-protected web server application to
transcribe the data into a custom-designed database, lo-
cated on a secure NHS server. The database has validation
on data fields.
Assessment and analysis of resource use
The pilot trial will assess the feasibility of collecting health-
care resource use data from the CRFs completed during the
admission and at the 4–8 week follow-up. Relevant resource
use is expected to fall under the following categories:
1. The wound dressing itself
2. Postoperative resources expended in the hospital setting
3. SSI-related care
4. Post-discharge resources expended in primary care
The analysis will involve an assessment of the quality and
completeness of the data for each data item, for example
data on type of wound dressing and frequency of use, and
other data on healthcare services provided in the hospital
setting (i.e. post-randomisation hospital stay and follow-up
outpatient appointments to assess wound healing). It will
also start to consider the main drivers of cost, so that these
can be accurately collected within the main trial.
Unit cost information associated with different types of
care will be collected or estimated in preparation for the
main trial and to ensure that these costs are available or
can be generated. Particular attention will be paid to un-
derstanding the costs associated with SSIs as preliminary
modelling suggests that these costs, rather than the costs
of dressings, are likely to be the main driver of any cost
differences between the arms of the trial. Preference-based
quality-of-life estimates for the entire cohort will be
derived by translating patients’ responses to the EQ-5D-5L
over the 4–8 weeks after randomisation into utility values
using the latest value set for England [23].
Trial duration
The trial is timetabled to take up to 11 months, rando-
mising the target number of 330 participants in nine
months and then following up the last participants for
4–8 weeks.Sample size
A pilot study of 920 eligible participants, will allow a re-
cruitment rate of 36% (corresponding to the target number
randomised of 330) to be estimated with a 95% confidence
interval (CI) of 32–39, and a recruitment rate of 60% with
95% CI of 56–64. For the simple dressings group, we antici-
pate an adherence rate of 90%. Assuming a 36% recruit-
ment rate and 110 randomised participants per group, a
90% adherence rate will be estimated with a 95% CI of 82–
95. We have no information on which to base any estimate
of adherence in the no dressing and glue-as-a-dressing
groups. However, if adherence were less than 70% in either
group, we would conclude that randomisation to the group
in question in the main trial would not be feasible.
Statistical analyses
Summary descriptive statistics to inform plans for the
main trial will be reported including:
1. The number of potentially eligible participants per
month per centre
2. The percentage of these potential participants
confirmed as eligible
3. The percentage of participants agreeing to be
randomly allocated to dressing type in the pilot RCT
4. The percentage of randomised participants receiving
the allocated treatment and completing outcome
measurements at the 4–8-week assessment
5. Rate of, and reasons for, non-adherence to allocation
at both a wound and participant level
6. Mean number of wounds per participant
7. Mean (or median if skewed) time from wound
closure to randomisation
8. Mean (or median if skewed) time to complete
randomisation process
9. Completeness of data items and reasons for missing
data
10. Rate of unblinding of outcome assessors and
reasons for unblinding
11. Secondary outcome measures relating to wound
closure will be compared between groups, if the data
allow
Only the statisticians will have access to the data. The
analysis population will include all randomised partici-
pants. Results will be described by centre and by spe-
cialty as well as overall. If the data allow, subgroup
analyses of the secondary outcome measures relating to
wound closure will estimate the interaction of timing of
randomisation by dressing group.
The primary analysis will take place when follow-up is
complete for all recruited participants. During the pilot
trial, we are monitoring recruitment and adherence peri-
odically. The study steering committee will review safety
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drawals after randomization, the data will be presented
by group with uninformative labels to keep the alloca-
tion masked.Dissemination
The results of the pilot trial will be reported in peer-
reviewed journals, in a report to the funder and as a lay
summary to participants. We will apply authorship criteria
established by the International Committee of Medical
Journal Editors.Changes to the protocol since first approved
This paper describes protocol version 5 (21 October
2016). Two substantial amendments have been approved.
Version 2 was the first approved protocol. The first
amendment (from v2 to v3) was approved (8 December
2015) before starting to recruit. Due to the short dur-
ation of the pilot trial, REC approval was obtained for a
design as conceived at the outset for the study, before
Phase A was completed. The first amendment described
revisions to this protocol that were required as a result
of the findings from Phase A [16]. The funding applica-
tion for the study always envisaged that Phase B would
be informed by Phase A. The time constraints for the
overall study (both Phase A and Phase B), combined with
the time needed to obtain REC approval, made it inevitable
that an amendment would be required after Phase A ended.
This amendment included: changing the trial population to
include patients having unplanned operations; substituting
the intervention of a complex dressing with glue-as-
a-dressing; and addition of the WMQ and WEQ as
secondary outcomes.
The need for a second amendment (v3 to v4, then to
v5 to accommodate a change requested by the REC)
arose from initial difficulties in recruiting patients having
unplanned surgery and obtaining patient-reported follow-up
questionnaires. This amendment (approved 6 September
2016) substituted a 4-h period between giving the PIL to a
potential participant and requesting consent by the state-
ment ‘as long as possible’, qualifying this as ‘usually more
than 4 hours for elective surgery and usually more than
1 hour for unplanned surgery’. We justified this on the basis
of feedback from trainee surgeons and research nurses that
potential participants did not require ‘thinking time’ in order
to decide whether to take part. We also revised the protocol
to allow the 4–8-week WHQ to be administered over the
telephone by a health professional, as well as face-to-face.
We applied for the trial to be adopted by the Health
Research Authority shortly after submitting the amend-
ment, in order to obtain approval for another NHS
Trust to recruit patients having abdominal surgery.Discussion
The short duration of the pilot trial, constrained by the
length of the overall research contract, has been a chal-
lenge. The design of pilot trial depended on the findings
of Phase A and the design was finalised shortly before
starting to recruit. Despite this, final preparation and the
two site initiation visits took place in just ten weeks, after
notification that the first amendment had been approved.
Development of the trial database was split into two re-
leases, one to allow recruitment and randomisation, and
the second for entry of data captured on paper CRFs.Status of the pilot trial
Recruitment is ongoing and is on target to achieve at the
pre-specified sample size in the scheduled time. The
interventions appear to be acceptable to potential par-
ticipants and over 50% of those who have been
approached to take part have given written consent.
After some initial deviations, adherence has also been
good; in particular, members of local research teams
have reported that the skin transfers are an acceptable
and effective way to promote adherence. Qualitative
interviews have also indicated that the interventions
are acceptable and that there have been few issues
with adherence. Further details about the feasibility
outcomes will be reported fully in due course.Additional files
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